Gilead Sciences, Inc. $GILD Shares Sold by Triglav Investments D.O.O.

Triglav Investments D.O.O. trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 21.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,000 shares of the biopharmaceutical company’s stock after selling 4,387 shares during the quarter. Triglav Investments D.O.O.’s holdings in Gilead Sciences were worth $2,230,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Brighton Jones LLC increased its stake in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $215,000. Sivia Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares during the period. Ieq Capital LLC grew its position in shares of Gilead Sciences by 12.0% during the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after buying an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC grew its position in shares of Gilead Sciences by 18.6% during the 2nd quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock valued at $516,000 after buying an additional 674 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent research reports. Rothschild & Co Redburn cut their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Truist Financial lowered their target price on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Morgan Stanley dropped their price target on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 8th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Daiwa Securities Group reduced their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Twenty-six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 83,000 shares of company stock valued at $10,824,500. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $129.83 on Monday. Gilead Sciences, Inc. has a 52-week low of $107.75 and a 52-week high of $157.29. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $161.19 billion, a price-to-earnings ratio of 17.69 and a beta of 0.32. The firm has a 50-day moving average price of $129.78 and a two-hundred day moving average price of $135.03.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business earned $1.81 earnings per share. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is 44.69%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.